This is reported by the Wall Street Journal.
According to the source, the reason for this decision was problems in the supply chain.
“Increasing the supply of raw materials took longer than expected. It is also important to emphasize that the results of clinical trials appeared later than initially predicted,” said Amy Rose, a Pfizer spokeswoman.
It is noted that the pharmaceutical giant was faced with the fact that some raw materials used in the early stages of production did not meet the necessary standards.
At the same time, Pfizer still expects to release more than a billion doses in 2021, as originally planned.